Dr. Daniel W. Clarke

With close to fifteen years of experience, Dr. Dan Clarke has developed a reputation for delivering high quality service when advising clients on their intellectual property matters. As a partner in the firm’s Intellectual Property group, he focuses on patent preparation and worldwide prosecution primarily in the life sciences industry. Dan has experience in a wide spectrum of life sciences technologies, including immunology (e.g., antibodies and chimeric antigen receptor (CAR) T cells), microbiology (e.g., probiotics and recombinant bacteria), genetics (e.g., gene editing and RNAi), oncology (e.g., immune checkpoint inhibitors and antigen-targeted nanoparticles), molecular diagnostics (e.g., biomarkers for disease detection and evaluation), molecular biology (e.g., next generation sequencing and single cell analysis systems), medical devices (e.g., biologically-enhanced scaffolds and microfluidics), tissue and cell engineering/regeneration (e.g., stem cell technologies), and small molecule therapeutics (e.g., new chemical entities for treatment of various diseases), among many others.

Dan's practice also involves performing due diligence evaluations of intellectual property portfolios including patentability, invalidity, non-infringement, and freedom-to-operate analyses. He works with a broad range of clients from academic institutions to small biotech start-ups and large pharmaceutical companies as well as the licensees of their intellectual property rights.